Akeso, Inc. (HKG:9926)

Hong Kong · Delayed Price · Currency is HKD

126.40

+2.70 (2.18%)

At close: Mar 27, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Research, Development, Production and Sale of Biopharmaceutical Products	3.06B	2.12B	4.53B	837.66M	225.63M
Research, Development, Production and Sale of Biopharmaceutical Products Growth	43.90%	-53.08%	440.35%	271.26%	-
Total	3.06B	2.12B	4.53B	837.66M	225.63M
Total Growth	43.90%	-53.08%	440.35%	271.26%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Mainland China	2.70B	1.88B	1.59B	837.66M	97.03M
Mainland China Growth	43.78%	17.85%	90.24%	763.33%	-
United States of America (USA)	338.52M	243.64M	2.93B	-	128.60M
United States of America (USA) Growth	38.94%	-91.69%	-	-	-
Other Regions	17.50M	2.26M	1.20M	-	-
Other Regions Growth	675.58%	87.53%	-	-	-
Total	3.06B	2.12B	4.53B	837.66M	225.63M
Total Growth	43.90%	-53.08%	440.35%	271.26%	-

Source: S&P Global Market Intelligence.